cmv gb vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1999 (NCT00125502)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cmv gb vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00299260 | Phase 2 | Aug 1, 2006 | National Institute of Allergy and Infectious Diseases (NIAID), University of London |
| NCT00133497 | Phase 2 | Jun 1, 2006 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00125502 | Phase 2 | Aug 1, 1999 | Icahn School of Medicine at Mount Sinai, National Institute of Allergy and Infectious Diseases (NIAID), Sanofi-Aventis, University of Alabama, Birmingham |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 1 | 1 | 1999 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 1999 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2006 |
5 organizations
Page 1 / 1